JP2006518383A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006518383A5 JP2006518383A5 JP2006503391A JP2006503391A JP2006518383A5 JP 2006518383 A5 JP2006518383 A5 JP 2006518383A5 JP 2006503391 A JP2006503391 A JP 2006503391A JP 2006503391 A JP2006503391 A JP 2006503391A JP 2006518383 A5 JP2006518383 A5 JP 2006518383A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- concentration
- acetate
- composition according
- glucocorticoid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 43
- 239000003862 glucocorticoid Substances 0.000 claims 6
- 229960002117 Triamcinolone Acetonide Drugs 0.000 claims 4
- YNDXUCZADRHECN-JNQJZLCISA-N Triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 4
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 claims 3
- 229960001487 RIMEXOLONE Drugs 0.000 claims 3
- QTTRZHGPGKRAFB-OOKHYKNYSA-N Rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 3
- 229960002800 prednisolone acetate Drugs 0.000 claims 3
- 229960001232 Anecortave Drugs 0.000 claims 2
- YUWPMEXLKGOSBF-GACAOOTBSA-N Anecortave Chemical compound O=C1CC[C@]2(C)C3=CC[C@]4(C)[C@](C(=O)COC(=O)C)(O)CC[C@H]4[C@@H]3CCC2=C1 YUWPMEXLKGOSBF-GACAOOTBSA-N 0.000 claims 2
- 206010030113 Oedema Diseases 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 230000001575 pathological Effects 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
Claims (16)
- 病的な眼の新脈管形成およびあらゆる関連する水腫を処置するための組成物であって、該組成物は、有効量の糖質コルチコイドおよび有効量の酢酸アネコルタブを含有する、組成物。
- 請求項１に記載の組成物であって、前記糖質コルチコイドが、トリアムシノロンアセトニド、プレドニゾロン、酢酸プレドニゾロン、リメキソロン、フルオロメタロン、酢酸フルオロメタロン、および薬学的に受容可能なそれらの塩からなる群より選択される、組成物。
- 請求項２に記載の組成物であって、前記糖質コルチコイドが、トリアムシノロンアセトニドである、組成物。
- 請求項３に記載の組成物であって、該組成物中のトリアムシノロンアセトニドの濃度が、０．４％ｗ／ｖ〜２．０％ｗ／ｖである、組成物。
- 請求項２に記載の組成物であって、前記糖質コルチコイドがリメキソロンである、組成物。
- 請求項５に記載の組成物であって、該組成物中のリメキソロンの濃度が、０．１％ｗ／ｖ〜４．０％ｗ／ｖである、組成物。
- 請求項２に記載の組成物であって、前記糖質コルチコイドが酢酸プレドニゾロンである、組成物。
- 請求項７に記載の組成物であって、該組成物中の酢酸プレドニゾロンの濃度が、０．１％ｗ／ｖ〜２．０％ｗ／ｖである、組成物。
- 請求項２に記載の組成物であって、前記糖質コルチコイドが酢酸フルオロメタロンである、組成物。
- 請求項９に記載の組成物であって、該組成物中の酢酸フルオロメタロンの濃度が、０．
１％ｗ／ｖ〜１．０％ｗ／ｖである、組成物。 - 請求項３に記載の組成物であって、該組成物中の酢酸アネコルタブの濃度が、０．１％ｗ／ｖ〜６％ｗ／ｖであり、かつ該組成物中のトリアムシノロンアセトニドの濃度が、０．５％ｗ／ｖ〜４．０％ｗ／ｖである、組成物。
- 請求項１１に記載の組成物であって、該組成物中の酢酸アネコルタブの濃度が、１％ｗ／ｖ〜３％ｗ／ｖである、組成物。
- 請求項１２に記載の組成物であって、該組成物中の酢酸アネコルタブの濃度が、３％ｗ／ｖである、組成物。
- 請求項１に記載の組成物であって、該組成物が、硝子体内注射、後強膜近傍送達、結膜下注射によってかもしくは移植されたデバイスを介した送達に適している、組成物。
- 請求項１４に記載の組成物であって、該組成物が、後強膜近傍注射による送達に適している、組成物。
- 請求項１４に記載の組成物であって、該組成物が、移植されたデバイスを介した送達に適している、組成物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44894403P | 2003-02-20 | 2003-02-20 | |
| PCT/US2004/003515 WO2004073608A2 (en) | 2003-02-20 | 2004-02-05 | Formulations of glucocorticoids to treat pathologic ocular angiogenesis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006326249A Division JP2007056041A (ja) | 2003-02-20 | 2006-12-01 | 病的な眼の新脈管形成を処置するための糖質コルチコイド処方物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006518383A JP2006518383A (ja) | 2006-08-10 |
| JP2006518383A5 true JP2006518383A5 (ja) | 2007-02-01 |
Family
ID=32908675
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006503391A Pending JP2006518383A (ja) | 2003-02-20 | 2004-02-05 | 病的な眼の新脈管形成を処置するための糖質コルチコイド処方物 |
| JP2006326249A Withdrawn JP2007056041A (ja) | 2003-02-20 | 2006-12-01 | 病的な眼の新脈管形成を処置するための糖質コルチコイド処方物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006326249A Withdrawn JP2007056041A (ja) | 2003-02-20 | 2006-12-01 | 病的な眼の新脈管形成を処置するための糖質コルチコイド処方物 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20040167109A1 (ja) |
| EP (1) | EP1594511A2 (ja) |
| JP (2) | JP2006518383A (ja) |
| KR (1) | KR20050102653A (ja) |
| CN (1) | CN100431544C (ja) |
| AR (1) | AR043252A1 (ja) |
| AU (1) | AU2004212900A1 (ja) |
| BR (1) | BRPI0407742A (ja) |
| CA (1) | CA2516790A1 (ja) |
| MX (1) | MXPA05008396A (ja) |
| PL (1) | PL378209A1 (ja) |
| RU (1) | RU2005129278A (ja) |
| TW (1) | TW200507858A (ja) |
| UY (1) | UY28203A1 (ja) |
| WO (1) | WO2004073608A2 (ja) |
| ZA (1) | ZA200505990B (ja) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2539023A1 (en) * | 2003-09-23 | 2005-04-14 | Alcon Inc. | Triamcinolone acetonide and anecortave acetate formulations for injection |
| US7257366B2 (en) * | 2003-11-26 | 2007-08-14 | Osmosis Llc | System and method for teaching a new language |
| AU2006287499A1 (en) * | 2005-09-07 | 2007-03-15 | Eliot M. Slovin | Biodegradable microparticle pharmaceutical formulations exhibiting improved release rates |
| US9693967B2 (en) | 2005-09-07 | 2017-07-04 | Southwest Research Institute | Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates |
| WO2007076437A2 (en) * | 2005-12-22 | 2007-07-05 | Alcon Research, Ltd. | C3-convertase inhibitors for the prevention and treatment of age-related macular degeneration in patients with at risk variants of complement factor h |
| US20070173538A1 (en) * | 2005-12-23 | 2007-07-26 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
| GB0625844D0 (en) * | 2006-12-22 | 2007-02-07 | Daniolabs Ltd | The treatment of macular degeneration |
| AU2007356856A1 (en) * | 2007-07-20 | 2009-01-29 | Alcon, Inc. | Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (RTKI) compounds to the eye |
| US8957052B2 (en) * | 2010-05-10 | 2015-02-17 | Universite Paris Descartes | Methods and compositions for the treatment of fluid accumulation in and/or under the retina |
| CA2951721C (en) * | 2014-06-12 | 2023-09-26 | The Research Foundation For The State University Of New York | Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4975537A (en) * | 1985-10-23 | 1990-12-04 | The Upjohn Company | Δ9(11) -angiostatic steroids |
| US4686214A (en) * | 1985-10-30 | 1987-08-11 | Alcon Laboratories, Inc. | Anti-inflammatory compounds for ophthalmic use |
| US4771042A (en) * | 1985-11-25 | 1988-09-13 | The Upjohn Company | Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments |
| US4853224A (en) * | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
| US5371078A (en) * | 1988-10-31 | 1994-12-06 | Alcon Laboratories, Inc. | Angiostatic steroids and methods and compositions for controlling ocular hypertension |
| US5164188A (en) * | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| US5378475A (en) * | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
| US5770592A (en) * | 1991-11-22 | 1998-06-23 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization using angiostatic steroids |
| US5556848A (en) * | 1993-12-27 | 1996-09-17 | Senju Pharmaceutical Co., Ltd. | Ophthalmic suspension containing diflupredonate |
| US5646136A (en) * | 1994-01-04 | 1997-07-08 | Duke University | Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids |
| US5516522A (en) * | 1994-03-14 | 1996-05-14 | Board Of Supervisors Of Louisiana State University | Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same |
| US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US5773019A (en) * | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
| US5736152A (en) * | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US6011023A (en) * | 1997-08-27 | 2000-01-04 | Alcon Laboratories, Inc. | Angiostatic steroids |
| DE60016271T2 (de) * | 1999-10-21 | 2005-12-01 | Alcon Inc. | Medikamentenzuführvorrichtung |
| CA2383572C (en) * | 1999-10-21 | 2007-12-11 | Alcon Universal Ltd. | Sub-tenon drug delivery |
| US6416777B1 (en) * | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
| RU2322239C2 (ru) * | 2002-08-05 | 2008-04-20 | Алькон, Инк. | Применение ацетата анекортава для защиты остроты зрения пациентов с возрастной дегенерацией желтого пятна |
-
2004
- 2004-02-05 BR BRPI0407742-3A patent/BRPI0407742A/pt not_active IP Right Cessation
- 2004-02-05 RU RU2005129278/14A patent/RU2005129278A/ru not_active Application Discontinuation
- 2004-02-05 CN CNB2004800043514A patent/CN100431544C/zh not_active Expired - Fee Related
- 2004-02-05 ZA ZA200505990A patent/ZA200505990B/xx unknown
- 2004-02-05 CA CA002516790A patent/CA2516790A1/en not_active Abandoned
- 2004-02-05 JP JP2006503391A patent/JP2006518383A/ja active Pending
- 2004-02-05 US US10/772,963 patent/US20040167109A1/en not_active Abandoned
- 2004-02-05 US US10/545,053 patent/US20060074061A1/en not_active Abandoned
- 2004-02-05 AU AU2004212900A patent/AU2004212900A1/en not_active Abandoned
- 2004-02-05 WO PCT/US2004/003515 patent/WO2004073608A2/en active Application Filing
- 2004-02-05 KR KR1020057015189A patent/KR20050102653A/ko not_active Application Discontinuation
- 2004-02-05 EP EP04708663A patent/EP1594511A2/en not_active Withdrawn
- 2004-02-05 PL PL378209A patent/PL378209A1/pl unknown
- 2004-02-05 MX MXPA05008396A patent/MXPA05008396A/es unknown
- 2004-02-19 UY UY28203A patent/UY28203A1/es not_active Application Discontinuation
- 2004-02-19 TW TW093104085A patent/TW200507858A/zh unknown
- 2004-02-20 AR ARP040100545A patent/AR043252A1/es not_active Application Discontinuation
-
2006
- 2006-12-01 JP JP2006326249A patent/JP2007056041A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020502197A5 (ja) | ||
| JP2006518383A5 (ja) | ||
| JP2008535850A5 (ja) | ||
| WO2006012227A3 (en) | Amido compounds and their use as pharmaceuticals | |
| JP2008044951A5 (ja) | ||
| WO2006020598A3 (en) | Amido compounds and their use as pharmaceuticals | |
| JP2010222367A5 (ja) | ||
| WO2006002361A3 (en) | 2-methylpropanamides and their use as pharmaceuticals | |
| JP2011516521A5 (ja) | ||
| JP2010132695A5 (ja) | ||
| RU2008118889A (ru) | Спососб лечения первичных и вторичных форм глаукомы | |
| MX340538B (es) | Compuestos amido y sus usos como farmaceuticos. | |
| SG163518A1 (en) | Amido compounds and their use as pharmaceuticals | |
| JP2006503913A5 (ja) | ||
| RS52199B (en) | PHARMACEUTICAL COMPOSITIONS OF THE NEUROACTIVE STEROID AND THEIR USE | |
| MX2009002314A (es) | Composiciones farmaceuticas que comprenden hgh para suministro oral. | |
| JP2009506071A5 (ja) | ||
| WO2006053172A3 (en) | The use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune diseases | |
| WO2007038138A3 (en) | Amido compounds and their use as pharmaceuticals | |
| WO2006123357A3 (en) | Oral controlled release composition containing levetiracetam | |
| WO2006012226A3 (en) | N-substituted piperidines and their use as pharmaceuticals | |
| WO2006055752A3 (en) | INHIBITORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1 AND METHODS OF USING THE SAME | |
| DE602005021909D1 (de) | Transdermale verabreichungssysteme | |
| WO2008062446A3 (en) | An extended release composition of levetiracetam, which exhibits no adverse food effect | |
| HRP20151202T1 (hr) | Oralna formulacija metadoksina |